Spero Therapeutics (NASDAQ:SPRO – Get Rating) had its price target cut by HC Wainwright from $7.00 to $6.00 in a research note published on Monday morning, The Fly reports. They currently have a buy rating on the stock.

Separately, Evercore ISI upgraded Spero Therapeutics from an in-line rating to an outperform rating and set a $8.00 price target for the company in a research note on Thursday, September 22nd. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $6.33.

Spero Therapeutics Trading Up 6.1 %

Shares of SPRO stock opened at $2.09 on Monday. Spero Therapeutics has a 1-year low of $0.68 and a 1-year high of $19.87. The company has a market capitalization of $73.29 million, a price-to-earnings ratio of -0.60 and a beta of 1.87. The stock's fifty day simple moving average is $0.95 and its 200-day simple moving average is $2.61.

Insider Buying and Selling at Spero Therapeutics

Institutional Investors Weigh In On Spero Therapeutics

A number of institutional investors have recently made changes to their positions in SPRO. Rock Springs Capital Management LP raised its position in Spero Therapeutics by 4.8% during the first quarter. Rock Springs Capital Management LP now owns 990,913 shares of the company's stock valued at $8,621,000 after purchasing an additional 45,600 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Spero Therapeutics during the first quarter valued at about $225,000. Eversept Partners LP acquired a new position in shares of Spero Therapeutics during the first quarter valued at about $519,000. AQR Capital Management LLC acquired a new stake in shares of Spero Therapeutics in the 2nd quarter worth about $115,000. Finally, XTX Topco Ltd acquired a new stake in shares of Spero Therapeutics in the 1st quarter worth about $115,000. Institutional investors own 57.38% of the company's stock.

Spero Therapeutics Company Profile

(Get Rating)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

See Also

• Get a free copy of the StockNews.com research report on Spero Therapeutics (SPRO)
• MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
• Is the Market Overreacting with Shopify Stock?
• MO Money: Why Altria Group Stock is Rallying
• Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
• Three Consumer Stocks That Could Outperform In Q4

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.